Pembrolizumab + Pemetrexed + Carboplatin + Cisplatin + Olaparib
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Nonsquamous Non-small-cell Lung
Conditions
Carcinoma, Nonsquamous Non-small-cell Lung
Trial Timeline
Jun 28, 2019 → Jan 29, 2026
NCT ID
NCT03976323About Pembrolizumab + Pemetrexed + Carboplatin + Cisplatin + Olaparib
Pembrolizumab + Pemetrexed + Carboplatin + Cisplatin + Olaparib is a phase 3 stage product being developed by Merck for Carcinoma, Nonsquamous Non-small-cell Lung. The current trial status is completed. This product is registered under clinical trial identifier NCT03976323. Target conditions include Carcinoma, Nonsquamous Non-small-cell Lung.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03976323 | Phase 3 | Completed |
Competing Products
20 competing products in Carcinoma, Nonsquamous Non-small-cell Lung